KASINGER JAMES R. sold $626K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 10,400 shares of CRISPR Therapeutics AG (CRSP) at $60.24 ($0.63M total) on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Sep 24, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, offering fresh data for traders.

02

Market read

Small insider sale may cause modest short-term price pressure but unlikely to move the broader market.

03

What to watch

Potential upcoming clinical data could offset negative sentiment.

Relevance 4/10Novelty 4/10Timing: filed Sep 24 2026

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

General Counsel James R. Kasinger sold 10,400 shares for $626,459 via a 10b5-1 plan.

Expected impact

Potential short-term dip of 1-2% as market digests insider sell.

Evidence & confidence

Sale size is modest but involves a senior officer; market may view as a slight bearish cue.

Market effects

Limited impact on biotech sector; similar insider sales are common.

No significant regional effect.

Minimal global relevance.

Counterpoint

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • James R. Kasinger

    General Counsel and Secretary of CRISPR Therapeutics AG.

  • CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$CRSPHighAI 8/10

Piper Sandler reiterates CRISPR Therapeutics stock rating at overweight

Piper Sandler maintained an Overweight rating and $110 price target for CRISPR Therapeutics (CRSP) after positive clinical data presentations. CTX310 showed significant reductions in lipid parameters, while zugo-cel demonstrated high response rates in various diseases. CRSP reported Q3 2026 sales of $99M for CASGEVY and holds $2.36B in cash. Analysts have mixed views on its valuation and price targets.

$CRSPMedAI 8/10

CRISPR Therapeutics reports trial results for gene therapy CTX310

CRISPR Therapeutics (CRSP) reported Phase 1b trial results for CTX310, a gene therapy for severe hypertriglyceridemia. The trial showed significant reductions in triglycerides, ANGPTL3 protein, and other cholesterol markers. No serious adverse events were reported. The FDA has granted RMAT designations to CTX310 for this indication and for elevated LDL cholesterol.